[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioage Labs Inc (BIOA)

Bioage Labs Inc (BIOA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 785,040
  • Shares Outstanding, K 44,453
  • Annual Sales, $ 9,000 K
  • Annual Income, $ -80,610 K
  • EBIT $ -102 M
  • EBITDA $ -102 M
  • 60-Month Beta 0.99
  • Price/Sales 92.49
  • Price/Cash Flow N/A
  • Price/Book 2.19

Options Overview Details

View History
  • Implied Volatility 88.63% (+15.07%)
  • Historical Volatility 66.34%
  • IV Percentile 13%
  • IV Rank 6.58%
  • IV High 632.70% on 05/21/25
  • IV Low 50.29% on 09/17/25
  • Expected Move (DTE 32) 3.49 (19.78%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 48
  • Volume Avg (30-Day) 557
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 9,002
  • Open Int (30-Day) 4,787
  • Expected Range 14.17 to 21.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.63
  • Number of Estimates 4
  • High Estimate $-0.54
  • Low Estimate $-0.68
  • Prior Year $-0.60
  • Growth Rate Est. (year over year) -5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.05 +10.03%
on 05/04/26
20.36 -13.26%
on 04/22/26
+0.69 (+4.07%)
since 04/15/26
3-Month
15.47 +14.16%
on 03/25/26
23.00 -23.22%
on 02/25/26
-1.91 (-9.76%)
since 02/13/26
52-Week
3.79 +365.96%
on 05/28/25
24.00 -26.42%
on 01/15/26
+13.84 (+362.30%)
since 05/15/25

Most Recent Stories

More News
BioAge Labs Enters Its First Quarter Judged Entirely on Pipeline Execution

Barchart Research What to Expect from BIOA Earnings BIOA Generated May 11, 2026 Current Price $18.16 EPS Estimate $$-0.69 Consensus Rating Moderate Buy Average Move 6.27% BioAge Labs Enters Its First Quarter...

BIOA : 17.66 (-5.64%)
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular...

BIOA : 17.66 (-5.64%)
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept...

BIOA : 17.66 (-5.64%)
Can BioAge Labs Break Its Pattern of Wider Losses Before Tomorrow's Report?

Barchart Research What to Expect from BIOA Earnings BIOA Generated May 4, 2026 Current Price $16.62 EPS Estimate $$-0.71 Consensus Rating Moderate Buy Average Move 6.27% Can BioAge Labs Break Its Pattern...

BIOA : 17.66 (-5.64%)
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease...

BIOA : 17.66 (-5.64%)
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all...

BIOA : 17.66 (-5.64%)
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...

BIOA : 17.66 (-5.64%)
Bioage Labs Faces Widening Losses as Analysts Watch Clinical Pipeline Ahead of Earnings

Barchart Research What to Expect from BIOA Earnings BIOA Generated March 25, 2026 Current Price $16.41 EPS Estimate $-0.74 Consensus Rating Moderate Buy Average Move 4.45% Bioage Labs Faces Widening Losses...

BIOA : 17.66 (-5.64%)
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025

Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory...

BIOA : 17.66 (-5.64%)
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...

BIOA : 17.66 (-5.64%)

Business Summary

BioAge Labs Inc. is a clinical-stage biopharmaceutical company. It involved in developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging. BioAge Labs Inc. is based in RICHMOND, Calif.

See More

Key Turning Points

3rd Resistance Point 19.08
2nd Resistance Point 18.68
1st Resistance Point 18.17
Last Price 17.66
1st Support Level 17.26
2nd Support Level 16.86
3rd Support Level 16.35

See More

52-Week High 24.00
Last Price 17.66
Fibonacci 61.8% 16.28
Fibonacci 50% 13.90
Fibonacci 38.2% 11.51
52-Week Low 3.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.